Brityn Lois Butrick was a light in the Turlock community, a woman whose grace and strength left an indelible mark on everyone she met. On Jan. 15, at the age of 42, Brityn completed a courageous four-year journey with cancer, leaving behind a legacy defined by faith, family, and an extraordinary capacity to love. Every life she touched was changed forever.

It is in Brytin’s honor that Legacy Health Endowment (LHE) is launching the Brityn Cares Cancer Medical Expense Relief Program. LHE’s goal is to assist families facing insurmountable hospital and physician bills for cancer that health insurance has shifted onto their shoulders. Whether a family is uninsured or under-insured, it can apply for relief at https://legacyhealthendowment.org/cancer-medical-debt-relief-program/.

In the U.S., great scientific discoveries and medical triumphs bring a troubling paradox: surviving cancer can too often mean going broke or constructing a pile of bills that seem insurmountable.

For some, cancer has quietly normalized a "second diagnosis" — financial toxicity — that shadows patients from the moment they hear the words "you have cancer." In a country that offers the most advanced treatments on earth, far too many patients must weigh life-saving therapy against the threat of foreclosure or bankruptcy.

Financial toxicity is not merely stress over money; it is a material harm that undermines clinical outcomes. High deductibles, percentage-based coinsurance, and out-of-network charges can easily create five-figure burdens for the patient. Even those with "good" insurance face early-year spikes in out-of-pocket costs that drain life savings before the first scan is even read.

The medical bills are only the beginning. Cancer demands a hidden infrastructure of uncounted costs: missed work, unpaid leave, long-distance travel to specialized centers, childcare, and the labor of family caregivers. These variables shape a patient's survival just as surely as a drug’s efficacy or a biomarker panel.

The burden is disproportionately borne by the most vulnerable — middle-income families, rural Americans, and gig workers. Many have insurance in name but not in protection — coverage that satisfies a regulatory requirement but leaves them exposed to catastrophic financial ruin.

The irony is painful. While American innovation in cancer treatment has accelerated beyond anything imagined a generation ago, our system for financing that care has remained stagnant. Manufacturers, insurers, and pharmacy benefit managers battle over pricing in ways almost entirely invisible to the patient — until the bill arrives. We celebrate "precision oncology," but the more precise the treatment, the more complex and expensive the care pathway becomes. Genomic sequencing and multidisciplinary teams are clinically appropriate, but they are also financially devastating under our current model.

Financial toxicity is not an unavoidable side effect of modern medicine; it is a policy failure. While bipartisan elected officials ignore the nuances of medical debt, the moral and economic question remains. We have made enormous strides in defeating cancer biologically. It is time we defeat its economic side effects as well.

In honoring the memory of Brityn — a local health advocate who was co-owner of La Mo Restaurant in downtown Turlock – we must ensure that the "cost of living" does not cost a family everything.

— Jeffrey Lewis is the President of Legacy Health Endowment. The words expressed are his own.